GG

Girish Ganpatbhai Mewada

Director DIN 07228531
DIN 07228531 First appointment Oct 2015
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2015
Shareholding value β€’β€’β€’β€’ Premium profile

About Girish Ganpatbhai Mewada

Data last updated:

Girish Ganpatbhai Mewada was a Director at Sushena Pharmaceuticals Private Limited (from 2021) and Designated Partner at Mercury Innovative Engineering Llp (from 2015).

DIN 07228531
First Appointment 06 Oct 2015
Oldest Company Age 11 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Aug 20212021Strike Off
Designated Partner06 Oct 20152015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sushena Pharmaceuticals Private Limited
Mercury Innovative Engineering Llp
Premium access

Shareholding and investment profile for Girish Ganpatbhai Mewada

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Girish Ganpatbhai Mewada

Girish Ganpatbhai Mewada was first appointed on 06 Oct 2015 as Designated Partner at Mercury Innovative Engineering Llp. The most recent appointment on record is 19 Aug 2021 at Sushena Pharmaceuticals Private Limited.

Girish Ganpatbhai Mewada held 2 earlier board appointments: Sushena Pharmaceuticals Private Limited (Director, from 19 Aug 2021); Mercury Innovative Engineering Llp (Designated Partner, from 06 Oct 2015).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available